Salvage therapies in relapsed and/or refractory myeloma: What is current and what is the future?

Nishitha Thumallapally, Hana Yu, Divya Asti, Adarsh Vennepureddy, Terenig Terjanian

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The treatment landscape for multiple myeloma (MM) is evolving with our understanding of its pathophysiology. However, given the inevitable cohort heterogeneity in salvage therapy, response to treatment and overall prognoses tend to vary widely, making meaningful conclusions about treatment efficacy difficult to derive. Despite the hurdles in current research, progress is underway toward more targeted therapeutic approaches. Several new drugs with novel mechanism of action and less toxic profile have been developed in the past decade, with the potential for use as single agents or in synergy with other treatment modalities in MM therapy. As our discovery of these emerging therapies progresses, so too does our need to reshape our knowledge on knowing how to apply them. This review highlights some of the recent landmark changes in MM management with specific emphasis on salvage drugs available for relapsed and refractory MM and also discusses some of the upcoming cutting-edge therapies that are currently in various stages of clinical development.

Original languageEnglish (US)
Pages (from-to)4843-4858
Number of pages16
JournalOncoTargets and Therapy
Volume9
DOIs
StatePublished - Aug 5 2016
Externally publishedYes

Fingerprint

Salvage Therapy
Multiple Myeloma
Therapeutics
Toxic Actions
Pharmaceutical Preparations
Research

Keywords

  • Multiple myeloma
  • Novel drugs
  • Relapsed and refractory myeloma
  • Salvage chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Salvage therapies in relapsed and/or refractory myeloma : What is current and what is the future? / Thumallapally, Nishitha; Yu, Hana; Asti, Divya; Vennepureddy, Adarsh; Terjanian, Terenig.

In: OncoTargets and Therapy, Vol. 9, 05.08.2016, p. 4843-4858.

Research output: Contribution to journalReview article

Thumallapally, Nishitha ; Yu, Hana ; Asti, Divya ; Vennepureddy, Adarsh ; Terjanian, Terenig. / Salvage therapies in relapsed and/or refractory myeloma : What is current and what is the future?. In: OncoTargets and Therapy. 2016 ; Vol. 9. pp. 4843-4858.
@article{408c6c6f95f4470e9244a344e788e462,
title = "Salvage therapies in relapsed and/or refractory myeloma: What is current and what is the future?",
abstract = "The treatment landscape for multiple myeloma (MM) is evolving with our understanding of its pathophysiology. However, given the inevitable cohort heterogeneity in salvage therapy, response to treatment and overall prognoses tend to vary widely, making meaningful conclusions about treatment efficacy difficult to derive. Despite the hurdles in current research, progress is underway toward more targeted therapeutic approaches. Several new drugs with novel mechanism of action and less toxic profile have been developed in the past decade, with the potential for use as single agents or in synergy with other treatment modalities in MM therapy. As our discovery of these emerging therapies progresses, so too does our need to reshape our knowledge on knowing how to apply them. This review highlights some of the recent landmark changes in MM management with specific emphasis on salvage drugs available for relapsed and refractory MM and also discusses some of the upcoming cutting-edge therapies that are currently in various stages of clinical development.",
keywords = "Multiple myeloma, Novel drugs, Relapsed and refractory myeloma, Salvage chemotherapy",
author = "Nishitha Thumallapally and Hana Yu and Divya Asti and Adarsh Vennepureddy and Terenig Terjanian",
year = "2016",
month = "8",
day = "5",
doi = "10.2147/OTT.S110189",
language = "English (US)",
volume = "9",
pages = "4843--4858",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Salvage therapies in relapsed and/or refractory myeloma

T2 - What is current and what is the future?

AU - Thumallapally, Nishitha

AU - Yu, Hana

AU - Asti, Divya

AU - Vennepureddy, Adarsh

AU - Terjanian, Terenig

PY - 2016/8/5

Y1 - 2016/8/5

N2 - The treatment landscape for multiple myeloma (MM) is evolving with our understanding of its pathophysiology. However, given the inevitable cohort heterogeneity in salvage therapy, response to treatment and overall prognoses tend to vary widely, making meaningful conclusions about treatment efficacy difficult to derive. Despite the hurdles in current research, progress is underway toward more targeted therapeutic approaches. Several new drugs with novel mechanism of action and less toxic profile have been developed in the past decade, with the potential for use as single agents or in synergy with other treatment modalities in MM therapy. As our discovery of these emerging therapies progresses, so too does our need to reshape our knowledge on knowing how to apply them. This review highlights some of the recent landmark changes in MM management with specific emphasis on salvage drugs available for relapsed and refractory MM and also discusses some of the upcoming cutting-edge therapies that are currently in various stages of clinical development.

AB - The treatment landscape for multiple myeloma (MM) is evolving with our understanding of its pathophysiology. However, given the inevitable cohort heterogeneity in salvage therapy, response to treatment and overall prognoses tend to vary widely, making meaningful conclusions about treatment efficacy difficult to derive. Despite the hurdles in current research, progress is underway toward more targeted therapeutic approaches. Several new drugs with novel mechanism of action and less toxic profile have been developed in the past decade, with the potential for use as single agents or in synergy with other treatment modalities in MM therapy. As our discovery of these emerging therapies progresses, so too does our need to reshape our knowledge on knowing how to apply them. This review highlights some of the recent landmark changes in MM management with specific emphasis on salvage drugs available for relapsed and refractory MM and also discusses some of the upcoming cutting-edge therapies that are currently in various stages of clinical development.

KW - Multiple myeloma

KW - Novel drugs

KW - Relapsed and refractory myeloma

KW - Salvage chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84988688653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988688653&partnerID=8YFLogxK

U2 - 10.2147/OTT.S110189

DO - 10.2147/OTT.S110189

M3 - Review article

C2 - 27540299

AN - SCOPUS:84988688653

VL - 9

SP - 4843

EP - 4858

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -